• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1-p-Aminoalkoxy phenyl-1-p-hydroxyphenyl-2-phenylalk-1-ene derivatives of the formula:… …<CHEM>… R1 = H, lower alkyl… R2 = lower alkyl… or R1 and R2 forms a heterocyclic radical with the adjacent N-atom… R3 = halogen or lower alkyl… R4 = H, halogen, OH, lower alkyl or forms with the benzene ring a naphthyl radical… n = 2, 3, 4, 5, 6… Possess anti-oestrogenic activity and are useful in the treatment of anovulatory infertility and of breast tumours. Representative of the compounds is I-(p-ss-dimethylaminoethoxyphenyl)-trans-I-p-hydroxyphenyl-2-p-tolylbut-I-ene.
    公开号:SU793382A3
    申请号:SU782652651
    申请日:1978-08-21
    公开日:1980-12-30
    发明作者:Нелли Ричардсон Дора
    申请人:Империал Кемикал Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    in a solvent in the presence of an acid binding agent l. Also known is a process for the preparation of triphenylalkylene amino esters of the formula II 1 C (CeH5) 0 (CftH5) R Rj where R, R ,, CjHg - or together with adjacent nitrogen form piperidium morpholyl or pyrrolide (et, n - 2 or and C -, alkyl, which is obtained by dehydration of the compound of formula IV C (OH) Sb1T5-SGN (Sb1GE) -T1z-CH (Sb115) -C (OH) (SbH5) -Ne R has the value given above using hydrochloric, hydrobromide, formic or phosphoric acid or a compound of formula T is obtained by reacting a compound of formula Ji M- (CH2) "- X, Where R and. R2 are the indicated values, and X is halogen; with a compound of formula VI NO-O-Ce CeHft where H is hydrogen or alkali metal. 1- (p - (- dimethylaminoethoxyphenyl) -trans-1n-hydroxyphenyl-2-phenylbut-1-n is known, which is the main metabolite of tamoxifen H. This invention relates to a method for producing triphenylalkene, which one of the phenyl radical in the 1 position has a hydroxyl group. According to the invention, the triphenylalkenes of the general formula VII (cng) "- where R is a hydrogen atom or an alkyl radical with a R2-alkyl radical with either R and 2 together with an az atom forms 5 - or b-membered heter cyclic radical; Rj is a halogen atom or a lower alkyl radical with C .; R4 is a hydrogen or halogen atom or a hydroxyl, or an alkyl radical with Sl, or a buta. A-1,3-dienyl radical forming a naphthyl radical with a benzene ring, n - 2-6, is obtained by dehydrating the corresponding alkanols of the general form in III H --- / «7 (СНг) - О - СН - / where R, R5) Rj. have the indicated meanings; a hydrogen atom or 2-tetrahydropyranyl, or methoxymethyl; R-J is a hydrogen or halogen atom, or an alkyl radical with or 1-3, 3-dienyl or R 2, O is an acid, for example, hydrochloric acid in a solvent, preferably ethanol, at a temperature of from 20 to 80 ° C. The compounds of formula I are formed as a mixture of cis and trans isomers. The latter can be separated by fractional crystallization or by chromatography. The compounds of formula I can be converted into salts with inorganic or organic acids in a conventional manner. Example 1: A solution of 1 (pp-dimethylaminoethoxyphenyl) -1-p- (2-tetrahydropyranyloxy) phenyl-2-phenylpropan-1-ol (3 g) in ethanol (50 ml) is acidified with concentrated hydrochloric acid and heated to reflux for 2 hours. The solvent is distilled off and the residue is stirred with water and alkalinized with ammonia solution. The precipitated base is extracted with diethyl ether, the ether extract is dried and evaporated to give a mixture of 1- (p-3-dimethylamino-ethoxy-phenyl) -l-p-hydroxy-phenyl-2-phenyl-propion-1-en-isomers. This mixture was stirred with chloroform (30 ml) and the insoluble residue was crystallized from acetone to give 1- (p-p-dimethylaminoethoxyphenyl) -cis-1-p-hydroxyphenyl-2-phenyl-prop-1-ene (500 mg); m.p. 178-180 ° C. The chloroform solution is evaporated and the residue triturated with chloroform. The mixture is filtered and the filtrate is evaporated. The residue is recrystallized from acetone to give 1- (pn-dimethylaminoethoxyphenyl) -trans-1-p-hydroxyphenyl-2-fench1prop-1-ene (83 mg); m.p. . Example 2 The procedure of Example 1 is used using an alkanol derivative of Formula IX C (OH) N- (CH2) n-o4 RS,
    TIR - 2-tetrahydropyranyl to obtain an alkene derivative having the formula X
    Biv
    - (smgio
    ng
    The output is given in abl. one.
    1) Isolated from a mixture of cis and trans isomers by chromatographic separation on silica plates (, 2 cm), 15 kg per plate, with double appearance at 10% v / v piperidine in toluene;
    RP 0.61.
    2) Isolated from a mixture of cis and trans isomers by chromatographic separation on silica (10 g per 1000 g of silica) with elution at 10 v / v. % piperidine / toluene,
    the subsequent extraction of the eluted material with boiling gasoline (bp 80-100 ° C) and recrystallization of the precipitated solid from toluene.
    3) Selected by rubbing the crude mixture of isomers with acetone and recrystallization of the solid thus obtained from acetone.
    Example 3. A solution of l- (n- | J-dimethylaminoethoxyphenyl) -1,2-di-p-hydroxyphenylbutan-1-ol (900 mg in ethanol / 90 ml) is acidified with concentrated hydrochloric acid and heated to reflux. for 3 hours. The solvent is distilled off and the residue is made alkaline by adding an alkaline ammonia solution. The precipitated solid is recirculated from acetone to give 1- (p- | b-dimethamino-ethoxyphenyl) -trans-1,2-di-p-hydroxyphenylbut-1-ena 37 mg; m.p. 250-252 ° C.
    Example 4. The procedure of Example 1 is used using 1- (p- | 4-dimethylaminoethoxyphenyl) (2-tetrahydropyranyloxy) -phenyl -2-phenylpentan-1-ol as the starting material to obtain 1- (p -p-dimethylaminoethoxyphenyl) - cis-1-p-hydroxyphenyl-2-phenylpent-1-ene; m.p. 126-130 s. .
    Example 5: A solution of 1- (pp-dimethylaminoethoxyphenol) (2-tetrahydropyranyloxy) phenyl -2-p-tolylbutan-1-ol (8.65 g) in ethanol (100 ml) is acidified with hydrochloric acid and heated to boiling under reflux for 3 hours. The solvent is distilled off and the reaction is made alkaline by adding an ammonia solution. The resulting mixture is extracted with ethyl acetate, and the extract is dried and evaporated to obtain a mixture of isomers 1- (p-p-dimethylaminoethoxyfanyl) -1- (p-hydroxyphenyl) -2-p-tolyl-but-1-en (2.6 g).
    A mixture of the above isomers (10 g) and chloroform (100 ml) is stirred and filtered, and the solid residue is crystallized twice from acetone. In this way, 1- (p-p-dimethylaminoethoxyphenyl) -cis-1-p-hydroxyphenyl-2-p-tolyl-but-1-ene (0.07 g) was obtained; m.p. 14b-148c.
    . ChlorosT) The normal filtrate is evaporated to
     dry residue and the residue is stirred with chloroform (50 ml). The mixture is filtered and the filtrate is evaporated to dryness. The residue is stirred with acetone (20 ml) and the mixture is filtered.
    5 The solid residue is recrystallized twice from acetone to give 1- (n-fi-dimethylaminoethoxyphenyl) -trans-1-p-hydrock (; ifyl-2-p-tolylbut-1-ena (0.25 g); mp; 184-187s.
    0 Example b. The procedure described in Example 5 is repeated using an alkanol derivative of formula XI
     (2} gs O - / 3- cioHlCH
    Tlo i
    Sgnb
    ) TPD XI
    where THP is 2-tetrahydropyranyl,
    to obtain an alkene derivative of formula XII
     / "- c" P g.
    (CH2) „- 0
    R
    The results are shown in Table. 2
    Example 7. The procedure described in Example 5 was repeated using appropriate 1- (p-dimethylamino-ethoxyphenyl) (2-tetrahydropyranyloxy) -phenyl-1-2-aryl-butane-1-ol as starting material. In this way were obtained alkene derivatives having the formula XIII
    GL
    X O.N.
    XIII
    The results are shown in Table. 3
    Isomer recovery procedure.
    A. Twerluk) is a mixture of parathiol isomers with petroleum ether, the solution is decanted, and the solid is triturated with chloroform. The solid residue is recrystallized twice from
    acetone to obtain the cis isomer; The chloroform mother liquors are evaporated to dryness, the residue is triturated with acetone, and the solid residue is crystallized twice from acetone to obtain the trans isomer.
    B. A mixture of isomers is triturated with acetone and the solid residue is crystallized from acetone to obtain the β-cisomer. Acetone stock solutions were evaporated to dryness and the residue was crystallized from acetone to give the trans isomer.
    C. A mixture of isomers is crystallized from acetone to obtain a solid trans isomer; The stock solutions are absorbed on silica gel, deactivating 12 w / w% water, and chromatographed on a similar column using a mixture of triethylamine and toluene, 1: 3 v / v, to obtain cis isomers.
    0. During the crystallization of the reaction mixture, only one isomer is obtained.
    Example 8. A solution of 4-dimethylaminoethoxy-c-ethyl-4-fluorodeoxy-6enzoin (3.2 g) in diethyl ether (30 ml) is added to a stirred Grivard reagent, prepared from a solution of p-methotoxymethoxybromobenzene (3.25 g) in tetrahydrofuran (30 ml) and a suspension of magnesium (0.36 g) in diethyl ether (30 ml) and the mixture is heated to reflux for 2 hours, cooled and decomposed by adding a solution of ammonium chloride (30 g) in water (100 ml) The organic layer is separated, the aqueous layer is extracted with diethyl ether and the combined organic solutions are dried and evaporated to dryness.
    The residue is stirred for 15 hours with isopropanol (20 ml), which contained a sufficient amount of water 10 and. hydrochloric acid to obtain a pH of 1, and the mixture is then evaporated to dryness. The residue is stirred with water with the addition of a concentrated solution of ammonium hydroxide, the mixture is made alkaline, followed by extraction with diethyl ether. The ethereal solution was extracted with 5% aqueous acetic acid (100 ml each) and the combined acid extracts were treated with charcoal and filtered, the solution was alkalified and extracted with diethyl ether. The extract is dried and evaporated to a dry residue, the residue is triturated with acetone. The solid product is crystallized from acetone to give 1- (dimethylaminoethoxyphenyl) -cis-1-p-hydroxyphenyl-2-p-fluorophenylbut-1-ene, m.p. 172174С.
    The acetone mother liquor is evaporated to a dry residue and the residue is crystallized from acetone to give 1- (n-p | -dimethylaminoethoxyphenyl-trans-1-p-hydroxyphenyl-2-p-fluorophenyl-but-1-ene; mp 152-154 ° WITH.
    Example 9. The procedure described in Example 1 was repeated using 1- (p) L-ethylamino-ethoxyphenyl) (2-tetrahydropyranyloxy) -phenyl -2-phenylpropan-1-ol as starting material. A mixture of isomers is triturated with petroleum ether (bp 40-BO ° C) and the solid residue obtained in this way is crystallized from isopropanol to give 1- (pn-ethylaminoethoxyphenyl) -cis-1-p-hydroxyphenyl-2-phenylpropyl 1-ene; m.p. 213-215®C. The isopropanol mother liquor is evaporated to a dry residue and the residue is crystallized from acetone to give 1- (p- |) -ethylamino-ethoxyphenyl) -trans-1-p-hydroxyphenyl-2-phenylprop-1-ene; m.p. 13413b ° C.
    Example 10. The procedure described in Example 1 was repeated using 1- (p-b-dimethylaminohexyloxyphenyl) (2-tetrahydropyranyloxy) -phenyl -2-phenylbutan-1-ol as the starting material. The resulting mixture of isomers is triturated with petroleum ether (bp 4 O-6 O C) and the solid residue is crystallized from acetone to give 1- (p-b-dimethylaminohexyloxyphenyl) -cis 1-p-hydroxyphenyl-2-phenyl-but-1-ene; m.p. 1b5-1b7 ° C.
    Table 1
    table 2
    hydrogen, an alkyl radical with 1-4 carbon atoms; an alkyl radical with 14 carbon atoms, or R - together in the nitrogen atom form a 5- or b-member-. ny heterocyclic radical; R is a halogen atom or an alkyl radical with 1 to 4 carbon atoms; - (p- | -dimethylaminoethoxyphenyl) -1 p-hydroxyphenyl-2-phenylbut-1-ene and its salts, characterized in that the acid of the acid is of the formula - (o
    where is Rj.R.R. have given
    higher values; hydrogen or 2-tetrahydropyranyl-, or methoxymethyl; K.J - hydrogen or halogen, or an alkyl radical with 1-4 atoms
    carbon, or 6-1,3-dienyl radical, or radical
    Formulas Rg, O,
    and the resulting product is isolated as a mixture of cis and trans isomers or
    in the form of individual isomers in its free form or in the form of a salt.
    Sources of information taken into account in the examination. 1, Patent of the USSR No. 450398, CL. C 07 C 93/06, published 07.09.75
    2. The patent of Germany No. 1468088,
    KL, C 07 C 93/06, published. 1372.
    3. Xenobiotica 1973, 3, 693. Priority signs by:
    08.22.77, where n 2-4.
    01/27/78, where n 2-6.
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining derivatives of triphenylalkenes of the general formula a hydrogen or halogen atom, or hydroxyl, or an alkyl radical with 1-4 carbon atoms, or a buta-1,3-dienyl radical, forming with a benzene ring where Ry is hydrogen, an alkyl radical of 1-4 carbon atoms;
    R 2 is an alkyl radical with 14 carbon atoms, or k < and R 2 ~ together in the nitrogen atom 'form a 5- or 6-membered heterocyclic radical;
    R-j is a halogen atom or an alkyl radical with 1-4 carbon atoms;
    a radical; η - .2-6, or their salts, with the exception of 1- (p-p-dimethylaminoethoxyphenyl) -1 p-hydroxyphenyl-2-phenylbut-1-ene and its
    Salts $ 5, characterized in that the dehydration is carried out acid alkanol of the formula in which s, Kd »R $. K; *, n have the above meanings;
    R ^ is hydrogen or 2-tetrahydropyranyl or methoxymethyl radical;
    k ^ is hydrogen or halogen, or an alkyl radical with 1-4 carbon atoms, or a buta-1,3-dienyl radical, or a 'radical of formula R 6 0, and the resulting product is isolated in the form of a mixture of cis and trans isomers or in the form of individual isomers in its. aqueous form or in the form of salt.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU793382A3|1980-12-30|Method of preparing triphenylalkene derivatives or their salts
    US3042685A|1962-07-03|Process of making g-fluoro tryptamine
    US2861072A|1958-11-18|Preparation of piperazine derivatives
    EP0249610B1|1993-08-25|Synthesis of optically active aryloxypropanolamines and arylethanolamines
    US3705907A|1972-12-12|4-|-3-aminopropoxy)-indole derivatives
    US4248884A|1981-02-03|2-Pyrrolidine methanol derivatives utilizable as medicaments
    US2695290A|1954-11-23|Derivatives of indole and method for the production thereof
    US3903164A|1975-09-02|Pharmacodynamically active amino alkyloxim ethers
    DE1770595B2|1974-07-11|2- | -7-nitro-1,2,3,4-tetrahydroquinoline derivatives and their pharmaceutically acceptable acid addition salts
    Yamato et al.1981|Synthesis and structure-activity relationship of spiro [isochromanpiperidine] analogs for inhibition of histamine release. 1
    DD266349A5|1989-03-29|PROCESS FOR THE PREPARATION OF 2-ACYLOXYPROPYLAMINE-2-ACYLOXYPROPYLAMINE DERIVATIVES
    RU2037494C1|1995-06-19|Derivatives of 2-azabicyclo-[2,2,1]-hept-5-ene-2-acetic acid
    US3164601A|1965-01-05|Analeptically active n-substituted aminonorcamphane derivatives and their acid addition salts and quaternary ammonium compounds
    US3056797A|1962-10-02|N-| ethyl-3-hydroxypiperidines
    Leonard et al.1950|Rearrangement of α-Aminoketones during Clemmensen Reduction. V. Influence of Alkyl Substitution on the α-Carbon1, 2, 3
    EP0025501B1|1982-12-29|N-aminoalkyl indole derivatives and their salts, processes for their preparation and medicaments containing these compounds
    US2878254A|1959-03-17|N, n&#39;-alkylene-bis-| compounds and preparation thereof
    US3116283A|1963-12-31|Preparation of nitrogen heterocyclic
    Fodor et al.1968|A direct, stereoselective synthesis of optically active conhydrines
    US3062839A|1962-11-06|Dihydroxy-tertiary-butylamines
    US2824111A|1958-02-18|Pyrrolidines
    US3024234A|1962-03-06|4-phenyl-4-alkanoyl-piperidine derivatives
    US3345411A|1967-10-03|2-alkyl-3, 3-diphenyl-propen-|-yl-amines and salts thereof
    CH460773A|1968-08-15|Process for the preparation of substituted 3- | -1-phenacyl-piperidines
    Marion et al.1944|The Synthesis of l-Roemerine1
    同族专利:
    公开号 | 公开日
    IL55387A|1982-07-30|
    NO145657B|1982-01-25|
    ES472742A1|1979-02-16|
    NZ188151A|1981-05-29|
    JPS5444644A|1979-04-09|
    CS208659B2|1981-09-15|
    BG30015A3|1981-03-16|
    EP0002097A1|1979-05-30|
    NO782768L|1979-02-23|
    AR218326A1|1980-05-30|
    ATA610378A|1980-01-15|
    IE781627L|1979-02-22|
    DD138313A5|1979-10-24|
    RO79083A|1982-06-25|
    IL55387D0|1978-10-31|
    EP0002097B1|1981-08-05|
    AU524339B2|1982-09-09|
    US4623660A|1986-11-18|
    DK370778A|1979-02-23|
    HU177650B|1981-11-28|
    YU199478A|1982-10-31|
    IT1098276B|1985-09-07|
    NO145657C|1982-05-05|
    CA1088950A|1980-11-04|
    FI782546A|1979-02-23|
    DE2860900D1|1981-11-05|
    AU3900678A|1980-02-21|
    AT358023B|1980-08-11|
    IE47237B1|1984-01-25|
    PT68458A|1978-08-30|
    IT7826930D0|1978-08-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB879792A|1956-11-06|1961-10-11|Richardson Merrell Inc|Preparation of substituted triphenylethylenes|
    BE635011A|1962-07-17|
    BE637389A|1962-09-13|
    US3288806A|1964-03-23|1966-11-29|Parke Davis & Co|Alpha--alpha-alkylstilbenes|
    GB1128379A|1966-06-20|1968-09-25|Ici Ltd|Novel alkene derivatives, process for the preparation thereof and compositions containing the same|
    US3576874A|1967-09-27|1971-04-27|Squibb & Sons Inc|2,2'''- bis )bis triethylamines|
    US3721712A|1968-08-19|1973-03-20|Richardson Merrell Inc|Aminoalkoxy-or aminomethyl-triarylalkenones|DE3046719C2|1980-12-11|1983-02-17|Klinge Pharma GmbH, 8000 München|1,1,2-Triphenyl-but-1-ene derivatives, processes for their preparation and pharmaceuticals|
    DE3239610A1|1982-10-26|1984-04-26|Klinge Pharma GmbH, 8000 München|NEW 1,1,2-TRIPHENYL-BUT-L-EN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|
    FR2558373B1|1984-01-20|1987-07-03|Mauvais Jarvis Pierre|ANTI-ESTROGEN MEDICINAL PRODUCT BASED ON 4-HYDROXYTAMOXIFENE FOR PERCUTANEOUS ADMINISTRATION|
    CA1289570C|1986-06-16|1991-09-24|Tetsuji Asao|1,1,2-triaryl-1-alkene derivatives|
    EP0287690B1|1987-04-21|1992-09-02|HEUMANN PHARMA GMBH &amp; CO|Stable solvent adducts of z-1--1--2-phenylbut-1-ene|
    US5204337A|1988-10-31|1993-04-20|Endorecherche Inc.|Estrogen nucleus derivatives for use in inhibition of sex steroid activity|
    US5364847A|1989-03-10|1994-11-15|Endorecherche|Inhibitors of sex steroid biosynthesis and methods for their production and use|
    JPH04312526A|1991-04-09|1992-11-04|Fujisawa Pharmaceut Co Ltd|Remedy for osteopathy|
    ZA924811B|1991-06-28|1993-12-29|Endorecherche Inc|Controlled release systems and low dose androgens|
    US5196435A|1991-11-21|1993-03-23|Eli Lilly And Company|Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma|
    DK0667768T3|1992-10-27|1999-09-27|Orion Yhtymae Oy|Use of toremifene for the treatment of SLE|
    US5525633A|1993-09-24|1996-06-11|Merrell Dow Pharmaceuticals Inc.|Triaryl-ethylene derivatives|
    HUT75933A|1993-09-24|1997-05-28|Merrell Pharma Inc|Triaryl-ethylene derivatives and pharmaceutical compositions containing the same|
    US5681835A|1994-04-25|1997-10-28|Glaxo Wellcome Inc.|Non-steroidal ligands for the estrogen receptor|
    US5604248A|1994-05-05|1997-02-18|Eli Lilly And Company|Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs|
    DE69529665T2|1994-06-27|2004-02-19|Neutron Therapies Inc., San Diego|HORMONE ANALOGS CONTAINING BOR AND METHOD FOR THEIR USE FOR IMAGING OR KILLING CELLS THAT HAVE HORMONE RECEPTORS|
    US5658931A|1994-09-20|1997-08-19|Eli Lilly And Company|Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds|
    US5554628A|1994-09-20|1996-09-10|Eli Lilly And Company|Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs|
    US5691384A|1994-11-29|1997-11-25|Hoechst Marion Roussel, Inc.|Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis|
    AU707290B2|1994-11-29|1999-07-08|Hoechst Marion Roussel, Inc.|Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis|
    US5763415A|1995-08-03|1998-06-09|John Hopkins University School Of Medicine|Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer|
    HN1996000101A|1996-02-28|1997-06-26|Inc Pfizer|COMBINED THERAPY FOR OSTEOPOROSIS|
    AT411016T|1997-08-15|2008-10-15|Univ Duke|PROCESS FOR THE PROPHYLAXIS OR TREATMENT OF ESTROGEN-DEPENDENT DISEASES|
    IL139015D0|1998-06-16|2001-11-25|Lilly Co Eli|Methods for increasing levels of acetylcholine|
    US6288108B1|1998-06-16|2001-09-11|Eli Lilly And Company|Methods for increasing levels of acetylcholine|
    GB9824207D0|1998-11-04|1998-12-30|Zeneca Ltd|Neurological disorders|
    HU0200871A3|1999-05-04|2004-04-28|Strakan Int Ltd|Androgen glycosides and androgenic activity thereof|
    US20020013327A1|2000-04-18|2002-01-31|Lee Andrew G.|Compositions and methods for treating female sexual dysfunction|
    AU781168B2|2001-01-26|2005-05-12|Pfizer Products Inc.|Method of treating certain cancers using an estrogen agonist/antagonist|
    US20020147187A1|2001-02-22|2002-10-10|Schmidt Jonathan Martin|1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof|
    JP2006501205A|2002-07-30|2006-01-12|カリキオンインコーポレイテッド|Ezetimibe composition and method for treating benign and malignant tumors associated with cholesterol|
    US7531578B2|2003-09-18|2009-05-12|City Of Hope|Compounds and methods for treating breast cancer and other diseases|
    MXPA06003122A|2003-09-19|2006-05-31|Pfizer Prod Inc|Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist.|
    US7829552B2|2003-11-19|2010-11-09|Metabasis Therapeutics, Inc.|Phosphorus-containing thyromimetics|
    MXPA06006810A|2003-12-17|2006-08-23|Pfizer Prod Inc|Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass.|
    EP3006039B1|2004-03-02|2021-01-06|Acceleron Pharma Inc.|Alk7 polypeptides for use in promoting fat loss|
    US20050203086A1|2004-03-04|2005-09-15|Pfizer Inc.|Methods of treatment using an EP2 selective receptor agonist|
    KR20070084455A|2004-11-23|2007-08-24|워너-램버트 캄파니 엘엘씨|7--3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia|
    US7741317B2|2005-10-21|2010-06-22|Bristol-Myers Squibb Company|LXR modulators|
    US7888376B2|2005-11-23|2011-02-15|Bristol-Myers Squibb Company|Heterocyclic CETP inhibitors|
    EP2034984A4|2006-06-02|2013-03-06|Pear Tree Women S Health Care|Method of treating atrophic vaginitis|
    WO2008070496A2|2006-12-01|2008-06-12|Bristol-Myers Squibb Company|N--2, 2--propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases|
    GB0715087D0|2007-08-03|2007-09-12|Summit Corp Plc|Drug combinations for the treatment of duchenne muscular dystrophy|
    AR068332A1|2007-08-03|2009-11-11|Summit Corp Plc|DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCLE DYSTROPHY|
    WO2009051908A1|2007-10-16|2009-04-23|Repros Therapeutics Inc.|Trans-clomiphene for metabolic syndrome|
    US20120046364A1|2009-02-10|2012-02-23|Metabasis Therapeutics, Inc.|Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use|
    GB2483736B|2010-09-16|2012-08-29|Aragon Pharmaceuticals Inc|Estrogen receptor modulators and uses thereof|
    CA2865234A1|2012-02-29|2013-09-06|Repros Therapeutics Inc.|Combination therapy for treating androgen deficiency|
    MX2014011217A|2012-03-20|2015-03-10|Seragon Pharmaceuticals Inc|Estrogen receptor modulators and uses thereof.|
    US9783519B2|2015-06-18|2017-10-10|Hong Kong Baptist University|Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities|
    AU2016352592A1|2015-11-10|2018-04-26|Paracrine Therapeutics Ab|Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen|
    WO2019103989A1|2017-11-22|2019-05-31|Temple University-Of The Commonwealth System Of Higher Education|Novel functionalized n,n-dialkylamino phenyl ethers and their method of use|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB3509377|1977-08-22|
    GB336478|1978-01-27|
    [返回顶部]